• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.

作者信息

Gez E, Goodman S, Isacson R, Gerra C, Sulkes A

出版信息

Oncology. 1986;43(3):173-5. doi: 10.1159/000226358.

DOI:10.1159/000226358
PMID:3754627
Abstract

Twenty-six patients with breast carcinoma who experienced severe emesis due to chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM). Most of the patients received the CMF (cyclophosphamide, methotrexate and 5-fluorouracil) combination chemotherapy. The MCP and DXM dosage were: 2 X 2 mg/kg and 2 X 0.2 mg/kg, respectively. In 41% of eighty evaluable courses, nausea and vomiting were eliminated altogether. The common side effects were: drowsiness, restlessness and diarrhea. HD-MCP and DXM are recommended in modified dose for preventing CMF chemotherapy induced emesis.

摘要

相似文献

1
High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.
Oncology. 1986;43(3):173-5. doi: 10.1159/000226358.
2
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.高剂量胃复安和地塞米松用于乳腺癌化疗门诊患者的止吐治疗。第二项研究。
Oncology. 1987;44(4):237-9. doi: 10.1159/000226485.
3
Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
Am J Clin Oncol. 1989 Dec;12(6):524-9. doi: 10.1097/00000421-198912000-00014.
4
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.在乳腺癌环磷酰胺、甲氨蝶呤和氟尿嘧啶化疗中，昂丹司琼与地塞米松和甲氧氯普胺作为止吐药的比较。
N Engl J Med. 1993 Apr 15;328(15):1081-4. doi: 10.1056/NEJM199304153281503.
5
High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.大剂量静脉注射甲氧氯普胺与大剂量甲氧氯普胺联合静脉注射地塞米松预防顺铂所致恶心和呕吐的比较：一项关于止吐疗效的单盲交叉对照研究
J Clin Oncol. 1985 Feb;3(2):245-51. doi: 10.1200/JCO.1985.3.2.245.
6
An audit of antiemetic use with CMF chemotherapy.
Clin Oncol (R Coll Radiol). 1998;10(5):313-7. doi: 10.1016/s0936-6555(98)80085-x.
7
Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study.
Oncology. 1989;46(3):150-4. doi: 10.1159/000226704.
8
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.化疗引起的呕吐：在轻度致吐性方案中对早期和延迟性呕吐的管理。
Cancer Chemother Pharmacol. 1996;38(5):471-5. doi: 10.1007/s002800050513.
9
Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
J Chemother. 1989 Dec;1(6):365-8. doi: 10.1080/1120009x.1989.11738924.
10
The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial.
Tumori. 1985 Oct 31;71(5):459-62. doi: 10.1177/030089168507100508.

引用本文的文献

1
Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.甲泼尼龙用于接受环磷酰胺、甲氨蝶呤和5-氟尿嘧啶治疗的乳腺癌患者的止吐治疗：一项比较两种不同剂量方案的前瞻性、交叉、随机双盲研究。
Cancer Chemother Pharmacol. 1992;30(3):229-32. doi: 10.1007/BF00686319.